The AAPS have published a handy pdf guide here. Some excerpts.
SARS-1 … had a case fatality rate of about 9.6%, … lasted about two seasons, and then subsided. … The virus was known to have escaped at least six times from several labs in China, causing illness outbreaks.
SARS-2 COVID-19 has been a different story. The actual infecting virus has been named SARS-2 or SARS-CoV-2 (Severe Acute Respiratory Syndrome 2) and is reported to be 79% identical to the genetic sequence of SARS 1. The name that was finally given to the “disease” is COVID-19 (short for Corona Virus Disease-2019). …
There are many viruses that contribute to the yearly cough, cold, flu, season. Rhinoviruses account for 35-70% of all symptoms, followed by coronaviruses at about 12-15% and then adenoviruses, and influenza viruses (7-12%). …
How deadly is covid?
The vast majority of deaths from this COVID virus occur in those 75 years old and older, with most of those already sick with other illnesses. A large percentage are in nursing care facilities, over 80 years old, and with an average of 2.5 other medical conditions, such as obesity, diabetes, heart disease, lung and/or kidney disease. …
The chances of someone under 50 years old with symptoms dying from COVID-19 is 0.05%. The chances of someone under 18 years old dying from COVID is near 0%. …
How it is more dangerous than the flu:
This virus looks and acts very much like the flu, but with one caveat: Unlike the usual seasonal influenza, COVID-19 illness can become profoundly serious in unpredictable ways.
COVID-19 can very rapidly become critical illness for two primary reasons: this viruses triggers two responses in the body much worse than seasonal flu:
- an exaggerated inflammatory response causing damage to critical organs, and
- an exaggerated blood-clotting response leading to multiple blood clots in the lungs, brain and other organs. Doctors have even found blood clots in large arteries like the aorta….
High risk patients:
Over age 50, with one or more other medical conditions:
• Obesity [usually defined by BMI >= 30]
• Diabetes, or pre-diabetes (“metabolic syndrome”)
• Lung disease (COPD, pulmonary fibrosis, asthma, cystic fibrosis)
• Kidney disease
• Autoimmune disorders
• History of cancer treatment
• History of taking corticosteroids regularly. …
For most people, the first symptoms are not that different from those you have had before at the beginning of a cold or flu. …
The three most critical symptoms of possible COVID are fever, shortness of breath/difficulty breathing/ pressure in your chest, and severe cough. Shortness of breath can mean shortness of breath at rest or even shortness of breath doing daily activities.
Keep a journal of your symptoms. It helps any doctors you consult know what has been happening if you keep a daily record of your symptoms by time and date and description of your illness.
Your journal can be life-saving when it comes time to see a doctor, especially in an emergency, since an accurate record of your symptoms, the timeline of when they started, how they progressed and how intense they are can help your doctor make better decisions about what you treatment you need.
Fresh air and vitamin D help:
Sunlight and fresh air are key components to good health and fighting COVID. Direct sunshine for 10-20 minutes twice a day is a good source of vitamin D. Studies are clear that low vitamin D is a risk factor for getting COVID and having a worse outcome and higher risk of dying. Vitamin D3 in oil in capsules is better absorbed than tablets and is an excellent source of supplemental vitamin D if you cannot be outside in the sunshine, or your blood level of vitamin D is too low.
Early treatment is essential, don’t wait for test results:
Because rapid treatment is so crucial in COVID, many outpatient physicians elect to treat their patients based on clinical symptoms, risk factors, and other objective findings from a physical exam or blood work and do not lose the “window of opportunity” for early treatment by waiting several days for a COVID test report. …
Studies … clearly show that patients who are treated within the first 5 days of symptoms have better outcomes using the combination of medications in the algorithm below. Conversely the death rate is ~12% by the time oxygen is needed, and ~40% for those requiring the intensive care unit. …
A “wait and see” approach is not adequate for high-risk patients … “Wait and see” is a factor contributing to the high death rate in the United States. Countries with the lowest death rates are treating early at home with the oral medicines listed in the algorithm that follows in this chapter. …
Most of our physician contributors recommend patients purchase a device worn on the finger to measure blood oxygen saturation, called an oximeter, available at local pharmacies for about $40-50.00 …
Early home-based treatment:
COVID-19 illness can become very serious, very rapidly, in unpredictable ways. While this does not happen to everyone, it is not possible to predict who will develop critical illness or how fast.
This unpredictability and rapid progression in COVID happen because the SARS-CoV-2 virus triggers TWO responses in the body that are much worse than seasonal flu:
- An exaggerated inflammatory response, causing damage to critical organs. In its most serious form, this is called cytokine storm.
- An exaggerated blood-clotting response, leading to multiple blood clots (thrombi) in the lungs, brain, kidneys, intestines and other critical organs. These blood clots in COVID can occur in both veins and arteries, which is unusual and potentially life-threatening if not treated rapidly. …
The basic groups of prescription medicines and other therapies used in COVID-19:
- Combination anti-viral medicines started as soon as symptoms occur
- Medicines to decrease inflammation, such as corticosteroids (called immunomodulators)
- Anticoagulant therapy to prevent blood-clots that can cause strokes, heart attacks, kidney shut-down, and death.
- Non-prescription supportive treatments with zinc, vitamin D, vitamin C, electrolyte drinks such as Pedialyte, and others.
- Home-based oxygen support, such as with an oxygen concentrator.
Antivirals in stage 1:
These must be started quickly at STAGE I (Days 1-5): Symptoms include sore throat, nasal stuffiness, fatigue, headaches, body aches, loss of taste and/or smell, loss of appetite, nausea, diarrhea, fever. These medicines stop the virus from (1) entering the cells and (2) from multiplying once inside the cells, and they reduce bacterial invasion in the sinuses and lung:
- Hydroxychloroquine (HCQ) with azithromycin (AZM) or doxycycline
- Ivermectin with azithromycin (AZM) or doxycycline
Either combination above must also include zinc sulfate or gluconate, plus supplemental vitamin D, and vitamin C. Some doctors also recommend adding a B complex vitamin.
Zinc is critical. It helps block the virus from multiplying. Hydroxychloroquine is the carrier taking zinc INTO the cells to do its job.
Anti-inflammatories in stage 2:
These are started at STAGE II (Days 3-14) to reduce inflammation, the cause of added damage to the lungs and critical organs. Symptoms include worsening cough, difficulty breathing, chest heaviness/tightness or chest pain. …
Anticoagulants (blood thinners) in stage 3:
STAGE III (Day 7 and beyond): Symptoms seen in Stage II intensify. Difficulty breathing becomes extreme, oxygen levels drop sharply, risk of heart attack or stroke increases. At this point, people are critically ill.
Prophylaxis means treatment designed to reduce risk of getting an illness. …
Very early on in the COVID pandemic, physicians in India, South Korea, Japan, Costa Rica, Turkey and several other countries began using the safe, widely available and very potent anti-viral medicine hydroxychloroquine (HCQ) as a prophylactic (preventive) medicine in COVID-19. The India Council on Medical Research (ICMR) published in March 2020 (updated in May, 2020) their national guidelines for India using HCQ 400 mg once a week for health care workers, physicians, nurses, first responders, high risk patients, and family members of exposed or COVID-positive individuals. Nations that employed widespread prophylaxis and early treatment with HCQ have had death and hospitalization rates much lower than nations where prophylactic and early treatment use of HCQ has not been recommended or widely available. ..
HCQ has a long half-life of about 22 days, so it can be given just once weekly for 8-12 weeks, or longer if someone is continually exposed to COVID, such as people working in hospitals. …
Some physicians prefer the anti-parasitic drug ivermectin for both prophylaxis and treatment. The initial dose recommendation was 0.2 mg/kg, but some are suggesting 0.4 to 0.6 mg/kg. …
We also believe that prophylactic therapy is the safest and most expedient way to help Americans reduce risk of getting sick with COVID, and be able to open schools, businesses and churches so we can overcome fear, and regain our freedom to live our lives again.
The most important consideration before approving a vaccine for human use is to make sure that the vaccine is safe and effective. Developing safe and controlled infection models for humans normally takes many years of phased testing in the lab, in animals, and then in humans. Many physicians and scientists have been concerned that vaccine manufacturers, with government support, are speeding up this process in ways that are not allowing adequate time for the usual phased testing leading up to human clinical trials.
No RNA-based vaccines were previously approved for human use. Vaccines for RNA viruses are notoriously challenging and difficult to develop. We still, after all these years since AIDS emerged in the 1980s, do not have a vaccine for the AIDS virus, or the SARS-1 coronavirus that emerged in 2002-2003, and both are RNA viruses.
Several attempts have been made to create vaccines for coronavirus and other respiratory viruses but none of the vaccines have survived the testing phases. The vaccine trial for SARS-1 from 2003, for example, was shut down because it produced autoimmune hypersensitivity reactions when exposed to the natural virus after immunization in animal studies.
Another problem is that the SARS-CoV-2 virus has already shown many mutations. Viruses adapt to the environment to survive.
Even the best vaccines for flu are only about 30-60% effective. Compare that with an effectiveness for improvement ranging from 64% to more than 90% in more than 100 new studies showing early, outpatient treatment for COVID-19 with our existing medications described in chapters.
Delayed side effects (e.g., infertility, cancer, autoimmune diseases) may not be seen for years. FDA has already issued warnings concerning blood clots, Guillain-Barré syndrome, and myocarditis/pericarditis. These may be rare or mild, but vigilance is needed so that early treatment can be offered. … Mild weakness should be taken seriously because it sometimes progresses rapidly to respiratory paralysis requiring mechanical ventilation.
We, of course, do not recommend anything. But this sort of information is not widely known, and has become almost politically incorrect amid the onslaught of pro-vaccine messages from the official sector.